Stream Link: https://event.arraylive.com/app/login/47fc2def-3789-4c44-8af4-8a2a6b2009c5/virtualattendee
Program Description
Small cell lung cancer (SCLC) is an aggressive and fast-growing type of lung cancer with a tendency for early, widespread metastasis. Around two-thirds of patients are diagnosed with extensive-stage SCLC (ES-SCLC), which involves distant metastases. Despite its aggressive nature, SCLC is initially sensitive to chemotherapy and radiation, yet patients often experience a high rate of relapse, underscoring the critical need for effective second-line and subsequent therapies. In this panel discussion, faculty will provide an in-depth, guideline-driven review of current standards and emerging treatment options for ES-SCLC, with a focus on addressing key challenges and gaps in care. The discussion will center on recent clinical data updates for novel agents and the evolving role of biomarkers in guiding treatment selection. Real-world operational and managed care strategies vital for optimizing patient outcomes, including facilitating timely access to care, enhancing medication coordination, navigating site-of-care considerations for novel therapies, and the essential role of managed care in preparing formularies and clinical pathways for rapid integration of new approvals, will be addressed.
Target audience: Managed care and oncology pharmacists
Type
of activity: Application
Release date: December 10, 2025
Expiration date: February 10, 2026
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine evolving treatment paradigms and updated clinical guidance for extensive-stage small cell lung cancer (ES-SCLC), with a focus on therapeutic sequencing beyond the first line
- Interpret emerging clinical data on novel and investigational therapies for advanced SCLC, including mechanisms of action, safety profiles, and potential integration into care pathways
- Apply managed care strategies to support timely access to evidence-based ES-SCLC therapies, addressing operational barriers and promoting equitable care delivery
